Recombinant Mouse TRAF-interacting protein with FHA domain-containing protein B (Tifab)

Shipped with Ice Packs
In Stock

Description

Regulation of TIFA–TRAF6–NF-κB Signaling

  • Mechanism: TIFAB binds monomeric TIFA, preventing its dimerization and subsequent TRAF6 recruitment, thereby suppressing NF-κB activation .

  • Structural basis: Crystal structures show TIFAB forms a heterodimer with TIFA, blocking TRAF6-binding motifs (Fig. 3A in ). Mutations at the TIFA-TIFAB interface (e.g., E61A, Y93A) abolish this inhibition .

  • Biological impact:

    • Reduces inflammatory responses in B cells and macrophages .

    • Downregulated during bacterial infection to permit NF-κB activation .

Hematopoietic Regulation

  • TRAF6 stability: TIFAB promotes lysosomal degradation of TRAF6, limiting TLR4-driven inflammation. Loss of TIFAB elevates TRAF6 levels, causing hyperactivation of immune pathways (e.g., IL-6, SOD2) in hematopoietic stem/progenitor cells (HSPCs) .

  • Myeloid malignancies:

    • Deletion of Tifab in mice mimics del(5q) myelodysplastic syndrome (MDS), leading to cytopenias and skewed myeloid differentiation .

    • Competitive transplants show Tifab-deficient HSPCs are outcompeted by wild-type cells due to p53 hyperactivation .

Experimental Models

StudyKey InsightCitation
TIFA/TIFAB complex analysisTIFAB suppresses ADP-Hep-induced NF-κB activation in HEK293T cells (luciferase assays)
Hematopoietic stressTIFAB loss sensitizes HSPCs to stress via USP15-MDM2-p53 axis dysregulation
Leukemia modelsTIFAB deletion in MLL-AF9 leukemia reduces leukemic cell survival

Tools and Reagents

  • Antibodies: Anti-TIFAB ZooMAb® (clone 1B15) detects endogenous TIFAB in THP-1 cells (KD = 1.4 × 10⁻⁶) .

  • Protein controls: Recombinant human TIFAB (aa 98–155) blocks antibody binding in IHC/WB at 100x molar excess .

Clinical and Therapeutic Implications

  • MDS/AML: TIFAB haploinsufficiency in del(5q) MDS correlates with TRAF6 accumulation and inflammatory HSPC dysfunction .

  • Therapeutic targeting: Restoring TIFAB expression or inhibiting TRAF6 rescues HSPC defects in preclinical models .

Product Specs

Form
Lyophilized powder
Note: We prioritize shipping the format currently in stock. However, if you have specific format requirements, please indicate them when placing your order, and we will fulfill your request.
Lead Time
Delivery time may vary depending on the purchasing method and location. Please consult your local distributors for specific delivery time information.
Note: All our proteins are shipped with standard blue ice packs. If dry ice shipping is required, please inform us in advance, as additional fees will apply.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Reconstitution
It is recommended to briefly centrifuge the vial before opening to ensure the contents are settled at the bottom. Reconstitute the protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. We suggest adding 5-50% glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our standard final glycerol concentration is 50%. Customers can use this as a reference.
Shelf Life
Shelf life is influenced by various factors, including storage conditions, buffer components, storage temperature, and the protein's intrinsic stability.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. For lyophilized form, the shelf life is 12 months at -20°C/-80°C.
Storage Condition
Store at -20°C/-80°C upon receipt; aliquoting is necessary for multiple uses. Avoid repeated freeze-thaw cycles.
Tag Info
Tag type will be determined during the manufacturing process.
Tag type is determined during the production process. If you have specific tag type requirements, please inform us, and we will prioritize the development of the specified tag.
Synonyms
Tifab; TRAF-interacting protein with FHA domain-containing protein B; TIFA-like protein
Buffer Before Lyophilization
Tris/PBS-based buffer, 6% Trehalose.
Datasheet
Please contact us to get it.
Expression Region
1-147
Protein Length
full length protein
Purity
>85% (SDS-PAGE)
Species
Mus musculus (Mouse)
Target Names
Tifab
Target Protein Sequence
MERPLTVLQV SLYHPTQGPV AFAHVPQQLQ HDASRLLVGR GQNTHLQLQL PQLSRYHLSL EPYLEKGSSL LAFCLKVLTR KSCVWVNGLP LRYLEQVPLG TINRISFSGI QMLVRKEGGA SLETFVCYFH LSPSPLIYRP KAQETDE
Uniprot No.

Target Background

Function
Inhibits TIFA-mediated TRAF6 activation, potentially by inducing a conformational change in TIFA.
Gene References Into Functions
  1. Retroviral insertional mutagenesis identified the del(5q) genes, CXXC5, TIFAB, and ETF1, along with the Wnt pathway, as potential targets in del(5q) myeloid neoplasms PMID: 26944478
  2. TIFAB loss increases TRAF6 protein levels and the dynamic range of TLR4 signaling PMID: 26458771
  3. Studies indicate that TIFAB is primarily expressed in B cells rather than T cells in the spleen. Findings suggest that TIFAB may function as a negative regulator of TRAF6-induced cellular functions, including B cell proliferation and maturation of dendritic cells and macrophages PMID: 19470519
Database Links

KEGG: mmu:212937

UniGene: Mm.116697

Tissue Specificity
Expressed at high levels in spleen and at moderate levels in lung, thymus, and small intestine.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.